Assay for Complement Inhibitors in Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for sickle cell disease only alleviate symptoms without addressing the underlying cause, and there is a need for improved methods to screen inhibitors effectively.
Innovation Solution
The development of model systems and assays to analyze the pathophysiology of sickle cell disease at cellular, tissue, and physiological levels, focusing on the complement pathway, particularly using alternative pathway inhibitors like C3, C5, and factor D inhibitors, to identify therapeutically useful compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current therapeutic drugs are used to treat sickle cell disease, then symptoms such as pain and anemia are reduced, but the underlying cause is not addressed
Solution Approach 1:
The patent converts the harmful effect of heme (which causes complement activation and sickling) into a beneficial diagnostic tool. By measuring complement activation in response to heme exposure, the assay identifies compounds that can inhibit the harmful complement pathway, thereby addressing the underlying cause rather than just masking symptoms
Solution Approach 2:
The patent uses complement activation as an intermediary mechanism to bridge the gap between sickle cell pathophysiology and drug screening. The complement pathway serves as a measurable mediator that reflects underlying disease mechanisms, allowing for the identification of compounds that target the root cause through inhibition of complement activation
2Reliability
If complement pathway inhibitors are identified through traditional screening methods, then therapeutic compounds can be found, but the screening process is complex and time-consuming
Solution Approach 1:
The patent extracts the essential function of complement activation from the complex sickle cell disease system and creates a simplified assay model. By isolating the complement activation response to heme exposure, the method creates a focused screening platform that maintains reliability in identifying therapeutic compounds while dramatically reducing the complexity of the screening process
Solution Approach 2:
The patent creates a simplified copy of the sickle cell disease pathophysiology in the form of an in vitro assay system. This copy uses cell lines and controlled heme exposure to replicate the essential complement activation mechanism, enabling high-throughput screening without the complexity of working with actual sickle cell patients or complex in vivo models
3Adaptability or versatility
If comprehensive screening of complement modulators is performed, then more therapeutic options are identified, but the assay throughput and efficiency are reduced
Solution Approach 1:
The patent designs a universal assay platform that can screen multiple types of complement modulators (C3 inhibitors, C5 inhibitors, factor B inhibitors, etc.) using the same basic protocol. The assay uses a standardized measurement of complement activation in response to heme exposure, allowing high-throughput evaluation of diverse compound classes without requiring separate assay protocols for each modulator type
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods allow for the identification of effective complement pathway inhibitors that significantly inhibit the pathophysiology of sickle cell disease, such as reducing complement activation on red blood cells and endothelial activation, thereby providing a potential therapeutic approach.
Implementation Method 1
heme induces activation of complement pathway, particularly complement C3 and/or C5b9 deposition, on cells
Implementation Method 2
measurement of the biological phenomena may be made in a high throughput format using a fluorescence assay (FACS) or enzyme-linked immunosorbent assay (ELISA)
Implementation Method 3
measurement of the biological phenomena may be made in a high throughput format using a fluorescence assay (FACS) or enzyme-linked immunosorbent assay (ELISA)
Data Source
AI summary
The present disclosure is directed to methods of identifying a test compounds for treating sickle cell disease (SCD), β-thalassemia (BT), or sickle cell BT. The methods involved contacting a test sample including cells with heme, serum, and a test compound, and measuring a biological phenomena including (1) deposition of a complement factor on the cells in the test sample; or (2) effect(s) of the complement factor deposition of (1) on target effector cells, where an attenuation in the biological phenomena in the test sample compared to the biological phenomena in a reference standard is indicative that the test compound is effective in treating sickle cell disease (SCD), -thalassemia (BT), or sickle cell BT.